Research

Hormonal

Tirzepatide demonstrates potential kidney-protective effects by slowing the decline in eGFR and reducing urinary albumin-to-creatinine ratio (UACR) compared to insulin glargine.

While not yet a primary indication, early data suggests tirzepatide may help protect kidney function in T2D patients, potentially slowing kidney disease progression compared to insulin. This benefit is observed even in patients already taking other kidney-protective medications.

ModerateQualifiesMEDIUM confidence
An exploratory analysis of the SURPASS-4 study suggested tirzepatide may have kidney-protective effects. Tirzepatide slowed the rate of decline in estimated glomerular filtration rate (eGFR) and reduced urinary albumin-to-creatinine ratio (UACR) compared with insulin glargine
Richard J. MacIsaac et al. · Diabetes Therapy · 2023

Why this rating

Based on an exploratory analysis of one phase 3 trial (SURPASS-4), not a dedicated kidney outcome trial.

Source

Challenging Clinical Perspectives in Type 2 Diabetes with Tirzepatide, a First-in-Class Twincretin

Richard J. MacIsaac et al. · Diabetes Therapy · 2023

DOI 10.1007/s13300-023-01475-5

narrative_reviewCited 14×
Read the paper
DOI resolved against Crossref · corpus check 2026-06-10

This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →